drugset / Trial / NCT02945163
Dosing of Tenofovir and Efavirenz in Antiretroviral Therapy
Phase 4
Completed
184 enrolled
Shanghai Public Health Clinical Center
The Second Hospital of Nanjing Medical University · collabYunnan Provincial Infectious Disease Hospital · collab
RandomizedParallel-groupOpen-labelTreatment
Summary
Tenofovir+lamivudine+efavirenz is still the first line regimen of combination antiretroviral therapy in developing countries. Based on our previous data, we aim to evaluate whether reduce the dose of tenofovir and efavirenz could decreasing the incidence of the side effects while not scarifying their virological efficacy.
Timeline
- Start
- 2018-03-05
- Primary completion
- 2019-06-05
- Completion
- 2019-08-31
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Efavirenz | Other / unclassified | 400 mg | Oral |
| Subject | Efavirenz | Other / unclassified | 600 mg | Oral |
| Subject | Lamivudine | Other / unclassified | 300 mg | Oral |
| Subject | Tenofovir | Small molecule | 200 mg | Oral |
| Subject | Tenofovir | Small molecule | 300 mg | Oral |